MAETZOLD DEREK J 4

What Happened

• Derek J. Maetzold, President & Chief Executive Officer of Castle Biosciences (CSTL), executed option exercises and multiple open-market sales on June 15, 2026. He exercised 550 shares at $2.39 (cost $1,315) and recorded another 550-share derivative conversion/transfer shown at $0.00. Separately, he sold a total of 86,192 shares in multiple open-market transactions at a weighted-average price of $20.66 for aggregate reported proceeds of $86,192. These transactions were reported on a Form 4 filed June 17, 2026.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 17, 2026 (timely).
• Sales: 86,192 shares sold in multiple trades; weighted-average sale price $20.66 (trades ranged $20.44–$20.98 per footnote).
• Option exercise: 550 shares exercised at $2.39 (cost $1,315); an additional 550-share derivative conversion shown with $0.00 value.
• Plan/authority: Sales executed pursuant to a Rule 10b5-1 trading plan adopted Dec 3, 2025 (footnote).
• Vesting: The option(s) involved are fully vested (footnote F13).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Other notes: Filing includes several family trust transfer footnotes dated June 10, 2026 describing reallocations among Maetzold trusts.

Context

• This pattern—exercising vested options and selling shares under a pre-established 10b5-1 plan—is common for executives managing option exercises, tax obligations, or diversification and does not by itself indicate a change in company outlook. The filing shows both an exercise and immediate sales (consistent with cashless or planned-sale treatment) and includes a zero-dollar derivative disposition that likely reflects a non-cash transfer or surrender as recorded on the Form 4.